Entrada Therapeutics (NASDAQ:TRDA) Director Sells $73,458.00 in Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Director Kush Parmar sold 10,494 shares of the company’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $7.00, for a total value of $73,458.00. Following the completion of the transaction, the director directly owned 2,836,098 shares in the company, valued at $19,852,686. This trade represents a 0.37% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Kush Parmar also recently made the following trade(s):

• On Monday, August 10th, Kush Parmar sold 92,444 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.00, for a total transaction of $647,108.00.
• On Friday, August 7th, Kush Parmar sold 52,317 shares of Entrada Therapeutics stock. The stock was sold at an average price of $6.85, for a total transaction of $358,371.45.
• On Friday, July 31st, Kush Parmar sold 1,718 shares of Entrada Therapeutics stock. The stock was sold at an average price of $6.85, for a total value of $11,768.30.
• On Thursday, July 30th, Kush Parmar sold 114,756 shares of Entrada Therapeutics stock. The shares were sold at an average price of $6.93, for a total value of $795,259.08.

Entrada Therapeutics Stock Performance

NASDAQ TRDA opened at $7.67 on Thursday. The company has a market capitalization of $298.67 million, a price-to-earnings ratio of -1.94 and a beta of -0.26. The company’s 50-day simple moving average is $6.89 and its two-hundred day simple moving average is $9.62. Entrada Therapeutics, Inc. has a one year low of $5.02 and a one year high of $16.45.

Entrada Therapeutics (NASDAQ:TRDA) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($1.01) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). The business had revenue of $0.90 million during the quarter, compared to the consensus estimate of $2.32 million. Entrada Therapeutics had a negative return on equity of 57.61% and a negative net margin of 3,537.73%. Equities analysts expect that Entrada Therapeutics, Inc. will post -4.04 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Entrada Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. State of Wyoming purchased a new position in Entrada Therapeutics in the second quarter worth approximately $37,000. Russell Investments Group Ltd. boosted its stake in Entrada Therapeutics by 72.7% in the third quarter. Russell Investments Group Ltd. now owns 8,808 shares of the company’s stock valued at $51,000 after acquiring an additional 3,707 shares in the last quarter. Occudo Quantitative Strategies LP acquired a new stake in shares of Entrada Therapeutics in the 2nd quarter valued at about $68,000. Jain Global LLC acquired a new stake in shares of Entrada Therapeutics in the third quarter valued at approximately $69,000. Finally, IHT Wealth Management LLC acquired a new stake in Entrada Therapeutics during the 2nd quarter worth $72,000. Hedge funds and other institutional investors own 86.39% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. Roth Capital reissued a “buy” rating and issued a $11.00 price target on shares of Entrada Therapeutics in a report on Wednesday. Weiss Ratings cut Entrada Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Thursday, June 11th. Guggenheim cut their price objective on shares of Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating for the company in a research report on Monday, June 8th. Finally, HC Wainwright downgraded Entrada Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday, May 8th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $17.75.

Key Stories Impacting Entrada Therapeutics

Here are the key news stories impacting Entrada Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS estimate to a loss of $4.19 from $4.33 and its FY2027 estimate to a loss of $3.13 from $3.14. The improved longer-term forecasts may be helping sentiment, although the firm maintained a Neutral rating.
• Neutral Sentiment: HC Wainwright slightly worsened its estimates for the third and fourth quarters of 2026, forecasting losses of $1.18 and $1.04 per share, respectively. The revisions suggest continued heavy spending and ongoing losses, with the firm’s full-year FY2026 estimate still below the current consensus loss estimate of $4.07 per share.
• Neutral Sentiment: Institutional ownership remains high at approximately 86.4%. BlackRock established a new position, while Millennium Management, Citadel Advisors and Qube Research increased their holdings. These institutional purchases may provide some support, although the reported transaction periods are inconsistent and should be interpreted cautiously.
• Negative Sentiment: Major shareholder Ventures V. L.P. 5Am sold 62,811 shares for approximately $431,829 across August 6 and 7. Director Kush Parmar also sold 155,255 shares for roughly $1.08 million from August 6 through 10. The sales reduced their respective holdings but did not represent complete exits, as both continued to own substantial positions. SEC insider transaction filings
• Negative Sentiment: Entrada’s latest quarterly results were weaker than expected: the company reported a $1.01-per-share loss versus the $0.97 consensus estimate and revenue of $0.90 million versus expectations of $2.32 million. As a clinical-stage biotechnology company, TRDA remains dependent on pipeline progress and future financing rather than current operating profits.

About Entrada Therapeutics

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.